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Abstract
Background: Nasopharyngeal carcinoma (NPC) is a malignant tumor which arises in surface epithelium of the posterior
wall of the nasopharynx. There’s is evidence that Epstein Barr virus (EBV) is associated to NPC development. However,
many epidemiologic studies point to a connection between viral infections by the human papillomavirus (HPV) and NPC.
Method: Seventy Moroccan patients with NPC were screened for EBV and HPV. EBV detection was performed by
PCR amplification of BZLF1 gene, encoding the ZEBRA (Z Epstein-Barr Virus Replication Activator) protein, and HPV
infection was screened by PCR amplification with subsequent typing by hybridization with specific oligonucleotides
for HPV types 16, 18, 31, 33, 35, 45 and 59.
Results: The age distribution of our patients revealed a bimodal pattern. Sixty two cases (88.9%) were classified as
type 3 (undifferentiated carcinoma), 6 (8.6%) as type 2 (non keratinizing NPC) and only 2 (2.9%) cases were
classified as type 1 (keratinizing NPC). EBV was detected in all NPC tumors, whereas HPV DNA was revealed in 34%
of cases (24/70). Molecular analysis showed that 20.8% (5/24) were infected with HPV31, and the remaining were
infected with other oncogenic types (i.e., HPV59, 16, 18, 33, 35 and 45). In addition, statistical analysis showed that
there’s no association between sex or age and HPV infection (P > 0.1).
Conclusion: Our data indicated that EBV is commonly associated with NPC in Moroccan patients and show for the
first time that NPC tumours from Moroccan patients harbour high risk HPV genotypes.
Background
Nasopharyngeal carcinoma (NPC) is a tumour that arises
in the epithelium surface of the posterior nasopharynx,
and shows a peculiar geographic and ethnic distribution.
The highest incidence rates of NPC are found among the
southern Chinese population and in isolated northern
populations such as Eskimos and Greenlanders (30 to 80
cases per 100,000 per year [1]. Intermediate incidence (8
to 12 cases per 100,000 per year) was reported in the Med-
iterranean basin, especially among the Arabic populations
of North Africa (7-10% of all cancers among men), where
NPC is also the commonest tumour of the ear, nose and
throat region [2,3]. The etiology of NPC seems to be mul-
tifactorial with evidence that genetic, viral and other envir-
onmental factors are involved together or separately,
simultaneously or consecutively [4].
Retrospectives and prospectives epidemiologic studies
have indicated the association between Epstein-Barr
virus (EBV), an ubiquitous human herpesvirus, and the
development of different malignancies, such as Burkitt’s
lymphoma, 40%-50% of Hodgkin’s disease, B-cell lym-
phoma in immunocompromised individuals, and NPC
[4,5]. Undifferentiated NPC is one of the most striking
examples of human malignancies that have been found
strongly associated with the EBV, and interest in human
papillomavirus (HPV) as a cofactor in NPC occurrences
has emerged over the last few years [6].
The papillomaviruses are small double-stranded DNA
viruses which infect squamous epithelia and display a
very high selectivity for the specific epithelium infected
[7,8]. More than 100 different HPV genotypes have been
described, but only 30 genotypes identified in the female
genital tract are associated with epithelial neoplasms
ranging from benign common warts to malignant carci-
noma of the uterine cervix [9]. It is widely reported that
in addition to HPV 16 and 18, which are frequently
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any medium, provided the original work is properly cited.found in association with cervical cancer (CC), HPVs 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82, while
other three as probable high-risk types (types 26, 53,
and 66) are also considered as carcinogenic [10].
According to their ability to transform epithelial
cells, HPV genotypes are divided into low-risk and
high-risk types. Low-risk types are associated with
benign lesions such as warts, while infections with
high-risk types progress to malignant lesions [8-10]. It
has been suggested that normal human oral epithelial
cells, especially nasopharyngeal cells, could be very
susceptible to persistent HPV and EBV co-infections
and that EBV and high-risk HPV co-infections may
play an important role in the initiation of a neoplastic
transformation of human oral epithelial cells [11]. To
date, different degrees of associations between HPV
and NPC have been described, yet no conclusive data
have been obtained. Given the particular characteristics
of NPC in the Moroccan population in terms of inci-
dence, age distribution and the predominance of speci-
fic EBV strains, we hypothesize that NPC tumours
from Moroccan patients harbour a specific HPV geno-
type. To our knowledge, this is the first study to
address the question of HPV implication as a pathoge-
netic cofactor in NPC patients from North Africa, and
the benefit of any additional knowledge that can be
used for detection cannot be overemphasized.
Results
The demographic characteristics of the 70 patients
showed that the mean age of patients was 39.65 with
extreme ages at 10 and 87 years old. The age distribu-
tion of our patients is represented in Figure 1 and
revealed a bimodal pattern. The first and second peak
correspond respectively to 11-20 and 51-60 years ranges.
The male-to-female ratio was 2.33 to1.
The pathological analysis was performed according to
the World Health Organization (WHO) classification
and revealed that among the 70 cases, 62 (88.9%) were
classified as type 3 (undifferentiated carcinoma), 6
(8.6%) as type 2 (non-keratinizing NPC) and only 2
(2.9%) cases were classified as type 1 (keratinizing NPC)
(Table 1).
The presence of amplifiable DNA, using primers for a
fragment of b-globin gene, was confirmed for all cases
and all DNA samples were adequate for further analysis.
Our results show that although all NPC biopsies were
EBV positive, HPV testing revealed the presence of HPV
DNA in 34% of NPC cases (24/70) (Table 1).
The distribution of HPV DNA in the 24 HPV positive
NPC cases is reported in (Table 1). Molecular analysis
showed that HPV31 was the most common subtype and
was present in 20.8% of HPV positive cases (5/24) and
HPV59 in 16.7% (4/24), whereas the other high risk
HPV 16, 18, 33, 35 and 45 were present in 8.3% (2/24),
8.3% (2/24), 4.2 (1/24), 4.2 (1/24) and 4.2 (1/24)
respectively.
Distribution of HPV genotypes according to the anat-
omy pathology status showed that among the 62 NPC
type III, 22 were HPV positive with a predominance of
HPV31 which was present in 22.7% of cases (5/22),
whereas, the only HPV-positive NPC type II biopsy was
HPV-18 positive and the only HPV positive NPC type I
was HPV-33 positive.
No statistically difference was observed in the HPV
prevalence between males (34.7%) and females (33%)
(Table 2), and no correlation between age and HPV sta-
tus was found (Table 3). The mean age of HPV-positive
Figure 1 Distribution of patients with NPC according to their age. For each age range, number of cases and percentage are given.
Laantri et al. Infectious Agents and Cancer 2011, 6:3
http://www.infectagentscancer.com/content/6/1/3
Page 2 of 6patients was 37.3, whereas the mean age of HPV-nega-
tive cases was 43.0 years (P > 0.1).
Discussion
It is widely accepted that EBV is etiologically associated
with NPC; but it is proven that other co-factors might
be involved in the carcinogenesis process. HPVs are
considered to be one of those factors since they possess
the ability to transform epithelial cells and a significant
number of NPC biopsies harbour HPV DNA [12,13].
We report here that 34% (24/70) from Moroccan NPC
biopsies harbour HPVs. These results are in agreement
with other studies reporting the same prevalence of
HPV DNA in NPC cases. In fact, using the same con-
s e n s u sp r i m e r s ,H P VD N Aw a sd e t e c t e di n3 1o f1 0 3
NPC samples (30%) [8]. Moreover, Krishna et al. have
shown that HPV DNA was detected in 38.8% of 36
southern Indian NPC cases [14]. Tung et al. in Eighty-
eight fresh tissue samples of NPC showed that HPV
DNA was detected in 51% of the specimens [15].
Coinfection by HPV and EBV has not been well docu-
mented and the significance of the presence of both
viruses in nasopharyngeal cells has not been determined.
In our study, coinfection with both viruses was observed
in 34% of patients. Tung et al. showed that among 88
fresh NPC specimens from Chinese population, coexis-
tence of EBV and HPV DNA was observed in 42% of
samples [15].
Of interest, EBV was detected also in CC specimens
from Indonesian patients, and 68% of analysed cases are
co-infected with HPV and EBV [16]. In our study, HPV
and EBV co-infection seems to be less frequent in NPC.
Theses differences may be due to the population’ char-
acteristics and the dissemination power of HPV in the
population.
Our results show no correlation between HPV status
with either age or gender in NPC patients. These
findings are supported by other studies that reported no
significant differences [17,18]. However, Zhang et al.
showed that HPV infection either in oral squamous cell
carcinoma or normal mucosa was observed with a
higher frequency in men (81.3%) compared with that in
women (60%) [19]. to evaluate the association between
HPV status and, age and/or gender, in NPC cases, a
study with a large sampling is needed.
With regard to HPV genotypes, HPV31 was the most
frequent genotype in Moroccan NPC patients (20.8%).
T h es a m eg e n o t y p ew a sa l s of r e q u e n t l yf o u n di nt o n s i l s
and nasopharyngeal cells in western Mexico NPC cases
[20]. The second prevalent HPV type detected in our
NPC biopsies is HPV59 (16,7%). Of interest, HPV-16
and -18, which are the most virulent genotypes asso-
ciated with CC in Moroccan woman (35% to 45%)
[21,22], were detected in very few Moroccan NPC cases
(8.3%), and similar data were reported in an Iranian
study [23].
Geographic and racial distinctions have been identified
between NPC of the Far East versus those diagnosed in
Caucasian American patients with regard to the interre-
lationship of histologic subtype and HPV infection. In
fact, HPV are detected more often (50%) in type I NPC
from American Caucasian patients than type III [6]. In
our study, one of two WHO-I and 22 of 68 WHO-II/III
NPCs tumors were HPV positive. The very low number
of NPC type-I cases available for comparison, reflecting
the rarity of WHO-I tumors in NPC patients from Mor-
occo, did not allow us to evaluate the relationship
between HPV and NPC histologic subtype.
Taken together, these data suggest that i) HPV geno-
types associated with NPC are different from those con-
sistently found in CC and ii) the HPV genotypes
associated with NPC are not geo-specific.
HPV and EBV co-infections have not been well
documented and the significance of the presence of
Table 1 Distribution of EBV and HPV infection in NPC cases
NPC cases N EBV+ HPV+ HPV 16 HPV 18 HPV 31 HPV 33 HPV 35 HPV 45 HPV 59 Untyped HPV cases
NPC type I 2 2 1 1
NPC type II 6 6 1 1
NPC type III 62 62 22 2 1 5 1 1 4 8
Total 70 70 24 2251114 8
N: Number of patients.
Table 2 Comparison of HPV positive cases between Male
and Female
Patients N HPV positive P - value
Male 49 17 0.869
Female 21 7
N: Number of patients.
Table 3 Comparison of age between HPV-positive and
HPV-negative cases
HPV infection N Mean age P - value
HPV positive cases 24 37.3 0.425
HPV negative cases 46 43.0
N: Number of patients.
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determined. It has been shown that ZEBRA, an EBV
immediate early protein expressed during lytic replica-
tion that activates early EBV genes, binds to p53 [24].
The physical interaction oft h eZ E B R Aa n dp 5 3p r o -
tein prevents p53 from activating p53-responsive pro-
moters [25,26]. Similarly, HPV has been found to
interact with p53, suggesting that this interaction pro-
motes cell growth and thereby enhance viral replica-
tion [27]. Targeting p53 may be a common
requirement for the replication of many types of DNA
viruses [16]. In addition, B cells transfected with EBV
latent membrane protein lost the regulatory effects of
the retinoblastoma (RB) protein, and the HPV E7 tran-
script has been shown to immunoprecipitate the RB
protein [28]. Thus, the functional loss of the RB pro-
tein might be one event common to both the HPV and
EBV carcinogenic pathways. Further investigations to
evaluate the expression of viral genes, especially the E6
and E7 oncogenes, are necessary to identify the possi-
ble role of HPV infection in NPC development. These
investigations could lead to the development of screen-
ing programs, new therapeutic approaches and specific
methods of prevention, especially in high incidence
areas.
On the other hand, further studies to evaluate the
impact of EBV and HPV coinfection in cervical and
nasopharyngeal carcinogenesis and molecular mechan-
isms implicated in tumor development are warranted.
Materials and methods
Samples
The analyses were performed on biopsies collected from
70 patients with histopathologically confirmed NPC at
the Oncology Centre in Casablanca, Morocco, after
informed written consent, as approved by the local Ethi-
cal Committee. The biopsies were stored at -80°C until
used.
DNA extraction
DNA extraction was perform e do nf r o z e nb i o p s ym a t e -
rial. The frozen tissues were homogenized and lysed in
digestion buffer (50 mM Tris-HCl, pH 8.5; 1 mM
EDTA and 0.5% Tween-20) containing 200 μgm l
-1 of
proteinase K. The samples were digested for 3 h at
55°C. Proteinase K was heat-inactivated at 95°C for 15
min. The samples were spin down and the supernatants
were collected and stored at -20°C until used. In order
to evaluate the efficiency of DNA extraction, all samples
were polymerase chain reaction (PCR)-amplified using
PC04 and GH20 primers specific for human b-globin
gene (Table 4).
PCR-quality control
To avoid contamination leading to false positive results,
all PCR-related work was carried out in specialized
zones within a PCR laboratory that undergoes UV puri-
fication at least once every 24 h. To detect crossover
contamination negative controls (PCR reagents contain-
ing no DNA) were included in each PCR amplification.
All negative controls were negative for b-globin and
HPV assay. Positive controls containing the SiHa and
Caski cell lines always amplified b-globin and HPV
DNA, respectively.
EBV Testing
Z-Epstein-Barr Virus Replication Activator (ZEBRA)
gene was amplified by PCR using ZES (forward) and
ZEAS (reverse) primers [29]. Primer sequences are
reported in Table 4. Briefly, 2 μLo fD N Aw e r es u b -
jected to PCR in a total volume of 50 μL, which includes
5 μL of Taq DNA polymerase buffer, 50 pM of ZES/
ZEAS primer mix, 0.2 μM of each dNTP (dATP, dCTP,
dGTP and dTTP), and 2.5 units of Taq DNA polymer-
ase (Promega Corp., Madison, WI). Samples were dena-
tured at 95°C for 5 min, then cycled 30 times through
1 min denaturation at 95°C, 2 min annealing at 58°C
and 2 min extension at 72°C. A final extension of 7 min
at 72°C was performed. The final PCR products were
analyzed by electrophoresis through a 1% agarose gel
stained by ethidium bromide and optically visualized by
ultraviolet transillumination.
HPV testing
DNA samples were amplified by PCR using consensus
primers MY09 and MY11 for a 450 bp target sequence in
t h eL 1r e g i o nt h a ti sh i g h l yc o n s e r v e do nab r o a ds p e c -
trum of HPV genotypes [29]. Each reaction mixture of
50 μl contained 50 pM of each primer, 0.2 μMo fe a c h
dNTP (dATP, dCTP, dGTP and dTTP), 0.625 units of
Taq DNA polymerase (Amersham Biosciences, Little
C h a l f o n t ,U K ) ,a n d3μL of DNA in Taq DNA polymer-
ase buffer. The mixture was first denatured at 94°C for
7 min, then cycled 35 times through 30 s denaturation at
94°C, 1 min annealing at 52°C and 1 min 30 s extension
at 72°C. A final extension of 7 min at 72°C was per-
formed. Aliquots of 10 μL of the PCR product were ana-
lysed by electrophoresis through a 1.2% agarose gel.
A representative gel is given in Figure 2. PCR products
were transferred into positively charged nitrocellulose
membranes (Hybond N+, Amersham) and fixed at 80°C
for 2 h. The membranes were hybridized under stringent
conditions using HPV specific biotinylated probes as
described previously [30]. The probes used in this study
were MY14, WD74, WD126, MY16, MY115, MY70 and
Laantri et al. Infectious Agents and Cancer 2011, 6:3
http://www.infectagentscancer.com/content/6/1/3
Page 4 of 6MY123 specific for HPV-16, 18, 31, 33, 35, 45 and
59 respectively (Table 4) [31]. Membranes were then
washed under normal and stringent conditions. Specific
hybrids were detected using a biotin luminescence detec-
tion kit (Biolabs, England) and the membranes were
exposed for 30 min to X-ray film (Hyperfilm ECL, Amer-
sham). An illustrative photo is given in Figure 3.
Statistical analysis
The results were analyzed statistically by the chi2 test.
The level of significance was set at 95% (a = 0.05) for
all tests.
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